uniQure rebounds after pipeline update

uniQure N.V. (NASDAQ:QURE) regained $1.02 to $19.80 on Tuesday after dipping 17% Monday on news announced along with 3Q15 earnings.

uniQure said it would not pursue FDA approval of Glybera alipogene tiparvovec. The gene therapy consisting of an adeno-associated virus (AAV) vector carrying lipoprotein lipase ( LPL) gene is approved in the EU to treat LPL deficiency. uniQure CEO Jorn Aldag told BioCentury in August that the company had "moved on from Glybera" (see BioCentury Extra, Aug. 27). ...